share_log

康健國際醫療：盈利警告

TOWN HEALTH: PROFIT WARNING

香港交易所 ·  Mar 14 06:34
Summary by Moomoo AI
康健國際醫療集團有限公司（「康健國際醫疗」）於2024年3月14日發布盈利警告，預告截至2023年12月31日止年度將錄得介乎約1.65億至2.23億港元的股東應佔綜合虧損，及介乎約1.35億至1.83億港元的綜合虧損。相比之下，2022年同期錄得約1,530萬港元的股東應佔綜合溢利及約4,950萬港元的綜合溢利。此次虧損的主要原因包括醫療服務需求增加、Central Medical Holdings Limited收購後的貢獻、投資物業公平值虧損增加以及資產減值虧損的大幅增加。公司目前正在對相關資產進行評估及估值，並將於年度業績公告中披露最終業績及其他詳情。
康健國際醫療集團有限公司（「康健國際醫疗」）於2024年3月14日發布盈利警告，預告截至2023年12月31日止年度將錄得介乎約1.65億至2.23億港元的股東應佔綜合虧損，及介乎約1.35億至1.83億港元的綜合虧損。相比之下，2022年同期錄得約1,530萬港元的股東應佔綜合溢利及約4,950萬港元的綜合溢利。此次虧損的主要原因包括醫療服務需求增加、Central Medical Holdings Limited收購後的貢獻、投資物業公平值虧損增加以及資產減值虧損的大幅增加。公司目前正在對相關資產進行評估及估值，並將於年度業績公告中披露最終業績及其他詳情。
Health International Medical Group Limited (“HealthCare International Medical”) issued a profit warning on 14 March 2024, expecting a consolidated loss of approximately HK$1.65 billion to HK$2.23 billion for the year ended 31 December 2023 and a comprehensive loss of approximately HK$1.35 billion to HK$1.83 million for the year ended 31 December 2023. In comparison, shareholders who earned approximately HK$1,530 million in the same period in 2022 accounted for a consolidated profit and an aggregate profit of approximately HK$4,950 million. The main reasons for this loss include increased demand for medical services, contributions following the acquisition of Central Medical Holdings Limited, increased losses in fair value of investment properties and a significant increase in asset impairment losses. THE COMPANY IS CURRENTLY EVALUATING AND VALUING THE RELATED ASSETS AND WILL DISCLOSE FINAL RESULTS AND OTHER DETAILS IN THE ANNUAL RESULTS ANNOUNCEMENT.
Health International Medical Group Limited (“HealthCare International Medical”) issued a profit warning on 14 March 2024, expecting a consolidated loss of approximately HK$1.65 billion to HK$2.23 billion for the year ended 31 December 2023 and a comprehensive loss of approximately HK$1.35 billion to HK$1.83 million for the year ended 31 December 2023. In comparison, shareholders who earned approximately HK$1,530 million in the same period in 2022 accounted for a consolidated profit and an aggregate profit of approximately HK$4,950 million. The main reasons for this loss include increased demand for medical services, contributions following the acquisition of Central Medical Holdings Limited, increased losses in fair value of investment properties and a significant increase in asset impairment losses. THE COMPANY IS CURRENTLY EVALUATING AND VALUING THE RELATED ASSETS AND WILL DISCLOSE FINAL RESULTS AND OTHER DETAILS IN THE ANNUAL RESULTS ANNOUNCEMENT.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more